Medtronic reports first quarter fiscal 2026 financial results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Medtronic, Inc. (mdt) PT Raised to $107 at Evercore ISI
August 19, 2025 4:15 PM EDTEvercore ISI analyst Vijay Kumar raised the price target on Medtronic, Inc. (NYSE: mdt) to $107.00 (from $106.00) while maintaining a Outperform rating.
The analyst comments "Thesis Update: Im in the EU & thought the Caesars phrase (w some tweaks) was apt in... More
TD Cowen Reiterates Buy Rating on Medtronic, Inc. (MDT)
August 19, 2025 8:32 AM EDTTD Cowen analyst Joshua Jennings reiterated a Buy rating and $106.00 price target on Medtronic, Inc. (NYSE: MDT).
The analyst comments "MDT reported F1Q'26 adjusted revenue of $8.54B with underlying organic growth of 4.8%. Reported revenue exceeded the $8.38B consensus target,... More
Truist Securities Reiterates Hold Rating on Medtronic, Inc. (MDT)
August 19, 2025 8:30 AM EDTTruist Securities analyst Richard Newitter reiterated a Hold rating and $92.00 price target on Medtronic, Inc. (NYSE: MDT).
The analyst comments "MDT's 4.8% organic rev growth was roughly in-line with 4.9% CNS, while higher reported rev (on FX) and (+$0.02 non-op items) drove a slight EPS beat ($1.26 vs CNS $1.23) on roughly... More
Goldman on Medtronic, Inc. (MDT), 'believe investors had expected total organic growth acceleration to follow the strong performance in CAS'
August 19, 2025 8:05 AM EDTGoldman Sachs analyst David Roman reiterated a Sell rating and $78.00 price target on Medtronic, Inc. (NYSE: MDT)
The analyst comments "This morning, Medtronic reported 1QFY26 that on a reported basis exceeded both GSe/Consensus (Visible Alpha consensus Data, unless otherwise noted). On an... More
Raymond James on Medtronic, Inc. (MDT) Earnings: 'All in, this result and guide fell short of our elevated expectations'
August 19, 2025 8:04 AM EDTRaymond James analyst Jayson Bedford reiterated a Market Perform rating and {REMOVEPT} price target on Medtronic, Inc. (NYSE: MDT).
The analyst comments "F1Q revenue beat consensus (by ~2%), but this was due to FX and Other revenue as organic growth of 4.8% y/y... More
Stifel Reiterates Hold Rating on Medtronic, Inc. (MDT)
August 19, 2025 8:01 AM EDTStifel analyst Rick Wise reiterated a Hold rating and $87.00 price target on Medtronic, Inc. (NYSE: MDT).
The analyst comments "Reporting yet another largely as expected quarter, F1Q26 performance was positively just above Consensus for both organic growth and EPS...and this... More
Mizuho on Medtronic, Inc. (MDT): 'Largely Inline Print Likely Overshadowed by New Board Appointees'
August 19, 2025 7:58 AM EDTMizuho analyst Anthony Petrone reiterated an Outperform rating and $100.00 price target on Medtronic, Inc. (NYSE: MDT)
The analyst comments "MDT reported a +$195mn/+$0.03 beat driven by strong performances across Cardiovascular (+$92mn ahead of Street), Diabetes (+22mn ahead of Street) and MedSurg... More
